Abstract

Background: Clonal hematopoiesis (CH) is characterized by expansion of hematopoietic stem cells due to somatic mutations in leukemia-associated genes. CH is associated with increased mortality, attributed to cardiovascular disease (CVD) driven by increased IL-1β from clonal macrophages. However, different CH-driver mutations perturb diverse genes with distinct functions and reports of IL-1β release from mutant macrophages are discordant. Furthermore, directionality of the association between CH and CVD is not established. Hypothesis: We hypothesized that mutations of common CH-driver genes have disparate effects on macrophage cytokine profiles and atherogenesis. We also hypothesized that atherosclerosis-driven systemic inflammation promotes clonal expansion. Methods/Results: We characterised cytokine expression in LPS-treated murine bone marrow-derived macrophages (BMDMs) harboring CH-driver mutations ( Tet2 , Dnmt3a , or Jak2 ). Transcript level of Il1a , Il1b and Il6 was increased ~3-5 fold in Tet2 -/- and Dnmt3a -/- BMDMs, but only ~1.5-2 fold with heterozygotic loss, which mimics more closely patients with CH. Notably, Tet2 -/- BMDMs (but not Dnmt3a or Jak2 ) release more IL-1α/β, accompanied by increased Asc specks and caspase-1 activity, implying heightened NLRP3 inflammasome activation. In murine chimera models of CH, Tet2 -/- and Tet2 +/- cells (but not Dnmt3a or Jak2 ), expand under the steady state. Clonal dynamics were unaffected by systemic inflammation via exogenous IL-1α, or high fat diet-induced atherogenesis in Ldlr -/- recipients. Atherosclerotic plaques in murine CH models at 12 weeks are only mildly increased with heterozygotic Tet2, Dnmt3a, or Jak2 mutations (10-20%). Observational and Mendelian randomisation analyses of UK BioBank did not reveal bidirectional associations between CH and atherosclerosis. Conclusions: We demonstrate augmented NLRP3 inflammasome activation in Tet2 -/- BMDMs and disparate effects of different CH mutations on cytokine profiles. We find no evidence for atherosclerosis or systemic inflammation driving clonal expansion. Thus, the pathogenesis of CH-driven disease should be treated as different entities for each mutation and likely involves overlapping or distinct mediators.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.